Susan Halabi

Overview:

Design and analysis of clinical trials, statistical analysis of biomarker and high dimensional data, development and validation of prognostic and predictive models.

Positions:

Professor of Biostatistics and Bioinformatics

Biostatistics & Bioinformatics
School of Medicine

Chief, Division of Biostatistics

Biostatistics & Bioinformatics
School of Medicine

Member of the Duke Cancer Institute

Duke Cancer Institute
School of Medicine

Education:

Ph.D. 1994

University of Texas Health Sciences Center at Houston

Grants:

PCRP Clinical Consortium: Duke University Clinical Research Site

Administered By
Medicine, Medical Oncology
Awarded By
Department of Defense
Role
Co Investigator
Start Date
End Date

Prognostic Models of Clinical Outcomes In Men With Castration Resistant Prostate Cancer

Administered By
Biostatistics & Bioinformatics
Awarded By
National Institutes of Health
Role
Principal Investigator
Start Date
End Date

Surrogate Endpoints of Overall Survival in Men with Metastatic Hormone Sensitive Prostate Cancer

Administered By
Biostatistics & Bioinformatics
Role
Principal Investigator
Start Date
End Date

Precision Medicine in Platinum-treated Lethal Bladder Cancer

Administered By
Biostatistics & Bioinformatics
Awarded By
Memorial Sloan Kettering Cancer Center
Role
Principal Investigator
Start Date
End Date

Serum Androgens and Survival in CRPC

Administered By
Duke Cancer Institute
Awarded By
University of California, San Francisco
Role
Principal Investigator
Start Date
End Date

Publications:

Abstract CT135: Cetuximab (C) in patients (Pts) with breast cancer (BC) and non-small cell lung cancer (NSCLC) without reportedKRAS, NRAS, BRAFmutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Authors
Fisher, J; Garrett-Mayer, E; Halabi, S; Mangat, PK; Alvarez, RH; Cannon, TL; Crilley, P; Pollock, T; Baghdadi, TA; Cotta, JA; Rygiel, AL; Antonelli, KR; Islam, S; Bruinooge, SS; Schilsky, RL
URI
https://scholars.duke.edu/individual/pub1416802
Source
crossref
Published In
Clinical Trials
Published Date
DOI
10.1158/1538-7445.am2019-ct135

Abstract CT146: Sunitinib (S) in patients (Pts) with metastatic colorectal cancer (mCRC) withFLT-3alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Authors
Alvarez, RH; Garrett-Mayer, E; Halabi, S; Mangat, PK; Baghdadi, TA; Ahn, ER; Chai, S; Rygiel, AL; Antonelli, KR; Islam, S; Bruinooge, SS; Schilsky, RL
MLA Citation
Alvarez, Ricardo H., et al. “Abstract CT146: Sunitinib (S) in patients (Pts) with metastatic colorectal cancer (mCRC) withFLT-3alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.” Clinical Trials, American Association for Cancer Research, 2019. Crossref, doi:10.1158/1538-7445.am2019-ct146.
URI
https://scholars.duke.edu/individual/pub1417295
Source
crossref
Published In
Clinical Trials
Published Date
DOI
10.1158/1538-7445.am2019-ct146

Clinical outcomes in Caucasian (C), African American (AA) and Asian men with metastatic castration-resistant prostate cancer (mCRPC).

Authors
Halabi, S; Dutta, S; Chi, KN; Tangen, CM; Petrylak, DP; Araujo, JC; Fizazi, K; Quinn, DI; Higano, CS; Tannock, I; Small, EJ; Kelly, WK
MLA Citation
Halabi, Susan, et al. “Clinical outcomes in Caucasian (C), African American (AA) and Asian men with metastatic castration-resistant prostate cancer (mCRPC)..” Journal of Clinical Oncology, vol. 37, no. 7_suppl, American Society of Clinical Oncology (ASCO), 2019, pp. 186–186. Crossref, doi:10.1200/jco.2019.37.7_suppl.186.
URI
https://scholars.duke.edu/individual/pub1417294
Source
crossref
Published In
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Volume
37
Published Date
Start Page
186
End Page
186
DOI
10.1200/jco.2019.37.7_suppl.186

Association of disease prognostic model (PM) with baseline quality of life (QOL) in metastatic castration resistant prostate cancer (mCRPC).

Authors
Prizment, A; Halabi, S; McSweeney, S; Eisenberg, A; Rao, A; Gupta, S; Morgans, AK; Ryan, CJ
MLA Citation
Prizment, Anna, et al. “Association of disease prognostic model (PM) with baseline quality of life (QOL) in metastatic castration resistant prostate cancer (mCRPC)..” Journal of Clinical Oncology, vol. 37, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2019, pp. e16579–e16579. Crossref, doi:10.1200/jco.2019.37.15_suppl.e16579.
URI
https://scholars.duke.edu/individual/pub1415557
Source
crossref
Published In
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Volume
37
Published Date
Start Page
e16579
End Page
e16579
DOI
10.1200/jco.2019.37.15_suppl.e16579

External validation of a prognostic model for overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC).

Authors
Halabi, S; Dutta, S; Araujo, JC; Logothetis, C; Sternberg, CN; Armstrong, AJ; Carducci, MA; Chi, KN; De Bono, JS; Petrylak, DP; Fizazi, K; Higano, CS; Small, EJ; Kelly, WK
MLA Citation
Halabi, Susan, et al. “External validation of a prognostic model for overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC)..” Journal of Clinical Oncology, vol. 37, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2019, pp. 5022–5022. Crossref, doi:10.1200/jco.2019.37.15_suppl.5022.
URI
https://scholars.duke.edu/individual/pub1415571
Source
crossref
Published In
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Volume
37
Published Date
Start Page
5022
End Page
5022
DOI
10.1200/jco.2019.37.15_suppl.5022

Research Areas:

Adenocarcinoma
Adenocarcinoma, Clear Cell
African Americans
Age Factors
Aged, 80 and over
Alkaline Phosphatase
Alleles
Arab countries
Area Under Curve
Biological Markers
Biomarkers, Pharmacological
Breast Neoplasms
Cancer Vaccines
Carcinoma
Carcinoma, Renal Cell
Case-Control Studies
Chemoprevention
Chemotherapy
Chi-Square Distribution
Clinical Trials, Phase II as Topic
Clinical trials
Cohort Studies
Computer Simulation
Confidence Intervals
Construction Materials
Contraceptives, Oral
DNA Damage
DNA Primers
DNA Repair
DNA, Neoplasm
Data Interpretation, Statistical
Decision Making
Decision Support Techniques
Diagnostic Imaging
Disease Progression
Disease-Free Survival
Drug Design
Dust
Efficiency, Organizational
Endpoint Determination
Equipment Design
Factor Analysis, Statistical
Family relationships
Gels
Gene Expression
Genes, Immunoglobulin
Genetic Predisposition to Disease
Genetics, Medical
Genotype
Germany
Graft vs Host Disease
HIV Infections
Hispanic Americans
Individualized Medicine
Kaplan-Meier Estimate
Ketoconazole
Lasso
Logistic Models
Lymphokines
Mining
Models, Biological
Models, Statistical
Models, Theoretical
Molecular Sequence Data
Multiprotein Complexes
Multivariate Analysis
Mutation
Neoplasms, Hormone-Dependent
Nomograms
Odds Ratio
Outcome Assessment (Health Care)
Ovarian Neoplasms
Personalized medicine
Population
Population Surveillance
Precision Medicine
Predictive Value of Tests
Pregnancy
Probability
Prognosis
Proportional Hazards Models
Prospective Studies
ROC Curve
Randomized Controlled Trials as Topic
Receptors, Progesterone
Registries
Reproducibility of Results
Research Design
Residence Characteristics
Retrospective Studies
Ribosomal Protein S6 Kinases
Risk
Risk Assessment
Risk Factors
Sample Size
Selective Estrogen Receptor Modulators
Sensitivity and Specificity
Statistics as Topic
Survival
Survival Analysis
Survival Rate
Tamoxifen
Translocation, Genetic
Treatment Failure
Treatment Outcome
Tumor Markers, Biological
United States
Urologic Neoplasms
Validation Studies as Topic
Vascular Endothelial Growth Factors